Romain C.
- Country
- France
- Department
- Pneumologie Oncologie
Research Overview
- Phase III Randomized Controlled Trial of Pembrolizumab with Platinum-Based Chemotherapy Versus Pembrolizumab Monotherapy in First-Line Treatment of NSCLC with PD-L1 ≥50%
- A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Data & Insights
Has run more than one trial at 242 of 488 partner sites.
Specializations
Non-Small Cell Lung Cancer Research
This investigator specializes in advancing treatment approaches for non-small cell lung cancer (NSCLC), with particular emphasis on managing advanced and metastatic disease states. Their research encompasses both early-stage and advanced disease management strategies.
- Advanced/Metastatic NSCLC Treatment
- Early-Stage Resectable NSCLC
- EGFR Exon 20 Insertion Mutations
Their work extends to investigating novel treatment combinations for various NSCLC subtypes and stages.
Immunotherapy Innovation
The investigator focuses on developing and evaluating novel immunotherapy approaches in lung cancer treatment, including combination therapies and innovative drug delivery methods.
- PD-L1 Expression Analysis
- Immunotherapy Combinations
- Targeted Therapeutic Approaches
Their research includes assessment of various immunotherapy agents and their efficacy in different patient populations.
Therapeutic Development
The investigator explores targeted therapeutic strategies for specific genetic mutations and biomarkers in lung cancer, including specialized treatment approaches for distinct patient subgroups.
- KRAS G12C Mutation Treatment
- Combination Therapy Assessment
- Treatment Resistance Management
Their work encompasses both conventional and emerging therapeutic modalities in lung cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.